EGFR Resistance in NSCLC:
Q2 2026 Intelligence Brief

MET amplification drives approximately 13% of acquired resistance events in patients receiving first-line osimertinib — higher than estimates derived from earlier biopsy-limited studies. A landmark analysis from the MARIPOSA trial, presented at WCLC 2025 and published in the Journal of Thoracic Oncology, quantified this precisely: 13.1% of patients at progression on osimertinib monotherapy harbored MET amplification, compared to only 3.4% in the amivantamab + lazertinib arm (P=0.002).

This translational dataset is significant for two reasons. First, it confirms MET bypass as the largest single druggable mechanism of acquired EGFR TKI resistance, larger than C797S, HER2 amplification, or transformation to SCLC. Second, it validates the mechanistic rationale for upfront EGFR/MET dual blockade — the combination literally suppresses the emergence of the dominant escape route.

Strategic implication:For programs developing MET inhibitors or MET-directed combination strategies, positioning post-osimertinib remains viable (since >10% of failures are MET-driven), but the MARIPOSA data will place competitive pressure on that space as amivantamab + lazertinib is adopted upfront.

The C797S gatekeeper mutation — arising at the cysteine residue that osimertinib and other third-generation EGFR TKIs require for covalent binding — has emerged in 6–12% of patients treated with first-line osimertinib, a higher frequency than observed in the post-second-generation TKI setting. C797S abrogates activity of all approved EGFR TKIs when it co-occurs with the sensitizing T790M mutation (as is typical with tertiary resistance), creating a patient population with few effective options.

Multiple programs are now targeting this mutation with allosteric (non-covalent) or mutant-selective fourth-generation approaches:

• BI 1810631 (Boehringer Ingelheim) — a non-covalent, wild-type-sparing fourth-generation EGFR TKI in Phase 1 (NCT04820023); early data published in 2024 indicate tolerability and preliminary anti-tumor activity in C797S-harboring tumors.
• BLU-701 (Blueprint Medicines / Roche) — an allosteric EGFR inhibitor designed to be active against C797S; Phase 1/2 SYMPHONY trial ongoing (NCT05276492).
• EAI045 + cetuximab (academic programs) — allosteric EGFR combination rationale being explored in translational models; clinical entry pending.

Strategic implication: C797S is an orphan-like space: a definable patient subgroup with no approved therapy and a growing Phase 1 competitive set. First mover with compelling Phase 2 data in 2026–2027 will have substantial partnership appeal.

The MARIPOSA trial (NCT04487080) randomized 1,074 patients with treatment-naïve EGFR-mutant (Ex19del or L858R) advanced NSCLC to amivantamab + lazertinib versus osimertinib. At the primary PFS analysis, the combination demonstrated a ~30% reduction in disease progression risk versus osimertinib (HR 0.70; P<0.001), establishing a new benchmark for first-line EGFR therapy.

Updated overall survival data presented at ELCC 2025 showed a statistically significant and clinically meaningful OS advantage for the combination arm — the first head-to-head OS benefit over osimertinib in EGFRm NSCLC. This was accompanied by mechanistic biomarker data confirming the differential resistance profile: fewer MET amplifications, fewer acquired EGFR secondary mutations, and a higher rate of patients without detectable ctDNA at progression in the amivantamab + lazertinib arm.

The central strategic tension: The combination also carries a substantially different toxicity profile (venous thromboembolism, dermatologic toxicity, infusion reactions from the IV amivantamab), and the subcutaneous amivantamab formulation (now approved) has reduced the administration burden. Whether US prescribers shift first-line standards is now the key market uptake question for 2026.

The MARIPOSA-2 trial (NCT04988295) evaluated amivantamab + lazertinib + carboplatin/pemetrexed versus carboplatin/pemetrexed alone in patients with EGFR-mutant NSCLC progressing on osimertinib. The amivantamab-containing arm demonstrated a 38% reduction in progression risk (HR 0.62), with benefits observed across molecular resistance subtypes including MET-amplified, C797S-harboring, and resistance-mechanism-indeterminate subgroups.

Updated analyses from Cancer Network (2025) confirm that amivantamab + chemotherapy maintains efficacy regardless of the dominant osimertinib resistance mechanism detected in ctDNA — an important practical point, since a significant proportion of patients (~30–40%) have co-occurring or uncharacterized mechanisms, and mechanism-agnostic efficacy is therapeutically valuable.

Practical implication: This positions amivantamab + chemo (now FDA-approved under the brand name RYBREVANT in this post-osimertinib combination setting) as a viable second-line backbone even without resistance mechanism testing — reducing the need for mandatory re-biopsy before therapy initiation.

Patritumab deruxtecan (HER3-DXd; Daiichi Sankyo / AstraZeneca) exploits the near-universal overexpression of HER3 on EGFR-mutant NSCLC cells. The HERTHENA-Lung01 trial (NCT04619004, Phase 2) enrolled 225 patients with EGFRm NSCLC who had progressed on prior EGFR TKI and platinum-based chemotherapy. The confirmed ORR was 29.8%, with a median duration of response of 6.4 months — activity observed across EGFR mutations, including uncommon variants, and regardless of prior osimertinib resistance mechanism.

HER3 protein expression, while nearly ubiquitous on IHC, was not strongly predictive of response in this dataset, suggesting that ADC delivery via the HER3 axis functions largely as a targeting mechanism for DXd payload delivery rather than requiring high-level HER3 signaling dependency.

Strategic implication: HER3-DXd provides a third-line (or later) option that is mechanism-agnostic with respect to EGFR resistance — potentially complementary to amivantamab-based strategies rather than competing directly. A Phase 3 confirmatory trial (HERTHENA-Lung02) is ongoing.

The availability of both osimertinib (with a known, manageable toxicity profile and established OS benefit over earlier TKIs) and amivantamab + lazertinib (with superior PFS and OS but greater toxicity burden) as first-line options has created a genuine clinical equipoise situation. Heather Wakelee (Stanford) and other key opinion leaders discussed this in depth at WCLC 2025: the identification of resistance mechanism at progression on osimertinib — via liquid biopsy — is now regarded as essential to guide salvage selection, with MET amplification directing capmatinib or tepotinib combinations, C797S directing enrollment onto 4th-gen TKI trials, and mechanism-indeterminate cases defaulting to amivantamab + chemotherapy.

The counter-argument for upfront amivantamab + lazertinib is that it suppresses resistance mechanism emergence at the source — reducing the probability of actionable resistance entirely. The individual patient data meta-analysis presented at WCLC 2025 (comparing amivantamab + lazertinib vs. osimertinib + chemotherapy) showed that the two regimens may have similar OS outcomes when accounting for post-progression therapy, suggesting that sequencing strategy may ultimately be equivalent if executed well.

Bottom line: The field is moving toward individualized sequencing algorithms based on patient fitness, MET/C797S/HER2 baseline status, and ctDNA monitoring — a trend that underscores the strategic value of liquid biopsy platforms and biomarker-informed clinical decision support tools.